AIHTA - Publications - Search - Items where Subject is "WP 800-910 Breast"
Number of items at this level: 57.

Fischer, S. and Zechmeister-Koss, I. (2012): Radiofrequency Ablation for the Treatment of Breast Cancer. Decision Support Document 57.

Frühwirth, I. and Wolf, S. (2022): Risk-based breast cancer screening in Austria: a systematic analysis of predictive models to assess individual breast cancer risk, their utility and applicability in a breast cancer screening programme. HTA-Projektbericht 145.

Grössmann, N. (2021): Tucatinib (Tukysa®) with trastuzumab and capecitabine for the treatment of HER2-positive locally advanced or metastatic breast cancer. Update April 2021. Oncology Fact Sheet Nr. 37.

Grössmann, N. (2021): Trastuzumab deruxtecan (Enhertu®) in patients with previously treated HER2-positive breast cancer. Update March 2021. Oncology Fact Sheet Nr. 32.

Grössmann, N. (2021): Alpelisib (Piqray®) plus fulvestrant for PIK3CA-mutated, hormone receptor–positive advanced breast cancer. Update February 2021. Oncology Fact Sheet Nr. 12.

Grössmann, N. (2021): A fixed-dose combination of pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) for the treatment of early and metastatic breast cancer. Update February 2021. Oncology Fact Sheet Nr. 30.

Grössmann, N. (2017): Abemaciclib (Verzenio®) in combination with fulvestrant for treatment of HR-positive, HER2-negative advanced breast cancer (ABC). DSD: Horizon Scanning in Oncology 72.

Grössmann, N. and Wolf, S. (2017): Neratinib for the treatment of patients with HER2-positive breast cancer after trastuzumab-based adjuvant therapy. DSD: Horizon Scanning in Oncology 66.

Jeitler, K. and Semlitsch , T. (2012): Everolimus (Afinitor® or Votubia®) in combination with exemestane in postmenopausal women with oestrogen receptor positive, HER2-negative locally advanced or metastatic breast cancer who are refractory to letrozole or anastrozole. DSD: Horizon Scanning in Oncology 32.

Jeitler, K. and Semlitsch, T. (2012): Bevacizumab (Avastin®) in combination with chemotherapy in previously treated metastatic breast cancer. DSD: Horizon Scanning in Oncology 27.

Jonas, S. and Schamberger, C. and Wild, C. (2002): [Predictive genetic diagnosis for breast and colon carcinoma: Diagnosis, treatment, public health aspects]. ITA-Projektbericht 21.

Jonas, S. and Wild, C. and Schamberger, C. (2003): [Predictive genetic testing for breast and colorectal cancer]. ZaeFQ: Zeitschrift für ärztliche Fortbildung und Qualitätssicherung 97 (01): pp. 67-71.

Jonas, S. and Wild, C. and Schamberger, C. (2002): Predictive genetic testing for mammary and colorectal cancer. Wiener Klinische Wochenschrift 114 Suppl. (17-18): p. 24.

Kirisits, A. and Wild, C. (2012): Efficacy of Hyperthermia Treatment in combination with radio- or chemotherapy in Breast-, Bladder-, Cervix Carcinoma and Soft Tissue Sarcoma patients. Update 2012. Decision Support Document 36 / Update 2012.

Korencan, A. (2007): [HER2 diagnostics in breast cancer]. HTA-Newsletter 55: pp. 3-4.

Korencan, A. and Guba, B. and Wild, C. (2007): Testing for HER2 positive breast cancer. Challenge for improvement of current conditions and practice. HTA-Projektbericht 08.

Mathis, S. and Garbaty , T. and Czeczot , J. and Maran , P.R. and Alberti, C. and Nachtnebel, A. (2011): Eribulin (Halaven®) as third- or late- line mono-therapy for advanced/metastatic breast cancer. DSD: Horizon Scanning in Oncology 18.

McGahan, L. (2019): Atezolizumab (Tecentriq®) with nab-paclitaxel (Abraxane®) for the treatment of advanced triple-negative breast cancer (aTNBC). DSD: Horizon Scanning in Oncology 87.

McGahan, L. (2018): Abemaciclib (Verzenio®) in combination with a nonsteroidal aromatase inhibitor (NSAI) as initial therapy for advanced breast cancer (ABC). DSD: Horizon Scanning in Oncology 78.

McGahan, L. (2017): Olaparib (Lynparza®) in patients with BRCA-mutated metastatic breast cancer. DSD: Horizon Scanning in Oncology 71.

McGahan, L. (2017): Palbociclib (Ibrance®) in combination with fulvestrant for the treatment of hormone-receptor-positive, HER2-negative advanced or metastatic breast cancer. DSD: Horizon Scanning in Oncology 64.

Nachtnebel, A. (2012): Pertuzumab (Omnitarg/Perjeta®) for the first-line therapy of metastatic HER2 positive breast cancer. DSD: Horizon Scanning in Oncology 31.

Nachtnebel, A. (2010): Lapatinib ditosylate (Tyverb/Tykerb®) as first-line therapy for the treatment of advanced/metastatic breast cancer. DSD: Horizon Scanning in Oncology 09.

Nachtnebel, A. and Polkowska, M. and Czeczot , J. and Joppi, R. and Poggiani, C. (2013): Trastuzumab emtansine (Kadcyla™) for previously treated patients with HER2-positive advanced/metastatic breast cancer . DSD: Horizon Scanning in Oncology 36.

Patera, N. and Wild, C. (2009): Status quo mammography screening: evaluation results from organised programs. HTA-Projektbericht 035.

Radlberger, P. (2006): [Predictive genetic diagnostics: Testing for breast cancer]. HTA-Newsletter 52: p. 2.

Radlberger, P. (2006): [Magnetic resonance imaging in patients with breast cancer]. HTA-Newsletter 51: pp. 2-3.

Radlberger, P. and Wild, C. and Guba, B. (2007): [Mammography screening. Evidence-based evaluation of mammography-based breast cancer screening programmes]. HTA-Projektbericht 07.

Rothschedl, E. and Wolf, S. (2022): Trastuzumab deruxtecan (Enhertu®) as monotherapy for the treatment of unresectable or metastatic HER2 positive breast cancer. Oncology Fact Sheet Nr. 102.

Rothschedl, E. and Wolf, S. (2022): Olaparib (Lynparza®) as monotherapy or in combination with endocrine therapy for the adjuvant treatment of patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer. Oncology Fact Sheet Nr. 104.

Rothschedl, E. and Wolf, S. (2022): Pembrolizumab (Keytruda®) in combination with chemotherapy as neo-adjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, for the treatment of locally advanced, or early‑stage triple‑negative breast cancer (TNBC). Oncology Fact Sheet Nr. 94.

Rothschedl, E. and Wolf, S. (2022): Abemaciclib (Verzenios®) in combination with endocrine therapy for the adjuvant treatment of early breast cancer. Update June 2022. Oncology Fact Sheet Nr. 84.

Rothschedl, E. and Nachtnebel, A. (2015): Bevacizumab (Avastin®) in combination with chemotherapy as second-line therapy for HER2-negative, locally recurrent or metastatic breast cancer that has progressed after first-line treatment with bevacizumab plus chemotherapy. DSD: Horizon Scanning in Oncology 51.

Schiller-Frühwirth, I. and Wild, C. and Geiger-Gritsch, S. and Mittermayr, T. (2009): Intraoperative radiotherapy for primary breast cancer. Systematic Review.. Decision Support Document 23.

Schiller-Frühwirth, I. and Wild, C. (2012): Intraoperative radiotherapy for primary breast cancer. Decision Support Document 23 / Update 2012.

Wild, C. (2007): [FDA: Safety warning on erythropoietin]. HTA-Newsletter 58: p. 4.

Wild, C. (2005): [Herceptin®/Trastuzumab for metastatic breast cancer]. HTA-Newsletter 40: p. 3.

Wild, C. (2005): [Computer-aided detection (CAD) in mammography]. HTA-Newsletter 37: pp. 2-3.

Wild, C. (2004): [Breast cancer care: Quality indicators]. HTA-Newsletter 32: p. 4.

Wild, C. (2004): [Sentinel node biopsy (SNB) in breast cancer]. HTA-Newsletter 24: pp. 2-3.

Wild, C. (2004): [Intraoperative radiotherapy in early stage breast cancer]. HTA-Newsletter 24: p. 4.

Wild, C. (2004): [Mammography screening in Austria. Editorial]. HTA-Newsletter 24: pp. 1-2.

Wild, C. (2004): [Breast cancer diagnosis by magnetic resonance imaging or positron emission tomography (PET)]. HTA-Newsletter 24: pp. 3-4.

Wild, C. (2004): [Epithelial cell cytology in breast cancer risk assessment]. HTA-Newsletter 24: p. 2.

Wild, C. (2003): [High-dose chemotherapy]. HTA-Newsletter 22: p. 4.

Wild, C. (2003): [Patient information in screening programmes. Editorial]. HTA-Newsletter 18: pp. 1-2.

Wild, C. (2003): [Digital mammography/DM]. HTA-Newsletter 15: pp. 2-3.

Wild, C. (2002): [Trastuzumab for breast cancer]. HTA-Newsletter 12: p. 2.

Wild, C. (2002): [Predictive genetic testing for breast and prostate cancer]. HTA-Newsletter 07: p. 2.

Wild, C. (2007): [FDA: Safety warning on erythropoietin]. ÖKZ: Österreichische Krankenhauszeitung 48 (07).

Wild, C. (2005): [Proton therapy]. HTA-Newsletter 43: p. 3.

Wild, C. (2001): Screening in Austria - the cases of mammography, PSA-testing and routine use of ultrasonography in pregnancy. International Journal of Technology Assessment in Health Care 17 (03): pp. 305-315.

Wild, C. and Jonas, S. (2002): [Predictive genetic testing for breast and colon cancer]. Newsletter der Österreichischen Gesellschaft für Public Health (3): p. 1.

Wolf, S. (2021): Sacituzumab govitecan (Trodelvy) as monotherapy for the treatment of patients with unresectable or metastatic triple-negative breast cancer (mTNBC). Update January 2022. Oncology Fact Sheet Nr. 70.

Wolf, S. (2021): Pembrolizumab (Keytruda®) in combination with chemotherapy for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC). Update February 2022. Oncology Fact Sheet Nr. 64.

Wolf, S. and Grössmann, N. (2017): Ribociclib in combination with letrozole for the first-line therapy of HR-positive, HER2-negative recurrent or metastatic breast cancer. DSD: Horizon Scanning in Oncology 65.

Zorginstituut Nederland (ZIN), EUnetHTA and Belgian Health Care Knowledge Centre (KCE), EUnetHTA (2018): MammaPrint® Added value of using the gene expression signature test MammaPrint® for adjuvant chemotherapy decision-making in early breast cancer. EUnetHTA report . HTA-Projektbericht 102.

This list was generated on Sat Sep 24 19:00:24 2022 CEST.